Progyny (NASDAQ:PGNY) Issues FY 2025 Earnings Guidance

Progyny (NASDAQ:PGNY) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 1.790-1.820 for the period, compared to the consensus estimate of 1.330. The company issued revenue guidance of $1.3 billion-$1.3 billion, compared to the consensus revenue estimate of $1.3 billion. Progyny also updated its Q4 2025 guidance to 0.370-0.400 EPS.

Analysts Set New Price Targets

Several analysts have recently weighed in on the company. Canaccord Genuity Group lifted their price objective on Progyny from $21.00 to $23.00 and gave the stock a “hold” rating in a report on Wednesday, August 20th. Weiss Ratings restated a “hold (c-)” rating on shares of Progyny in a research report on Wednesday, October 8th. Cantor Fitzgerald restated an “overweight” rating and set a $28.00 target price (up previously from $26.00) on shares of Progyny in a research report on Friday, August 8th. JPMorgan Chase & Co. upped their price objective on Progyny from $23.00 to $25.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 26th. Finally, Truist Financial boosted their price target on Progyny from $24.00 to $27.00 and gave the stock a “hold” rating in a research report on Thursday, July 17th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Progyny currently has a consensus rating of “Moderate Buy” and a consensus price target of $25.44.

Progyny Price Performance

PGNY stock traded down $0.87 during midday trading on Thursday, reaching $18.01. 1,889,092 shares of the stock were exchanged, compared to its average volume of 1,394,061. The stock has a market capitalization of $1.55 billion, a PE ratio of 30.53, a P/E/G ratio of 1.58 and a beta of 1.29. Progyny has a 52 week low of $13.39 and a 52 week high of $26.76. The company has a fifty day moving average price of $21.04 and a 200 day moving average price of $21.87.

Progyny (NASDAQ:PGNY) last announced its quarterly earnings data on Thursday, November 6th. The company reported $0.15 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.22). Progyny had a net margin of 4.28% and a return on equity of 10.69%. Progyny has set its FY 2025 guidance at 1.790-1.820 EPS. Q4 2025 guidance at 0.370-0.400 EPS. As a group, analysts anticipate that Progyny will post 0.6 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Allison Swartz sold 2,398 shares of the firm’s stock in a transaction dated Thursday, August 28th. The stock was sold at an average price of $22.96, for a total value of $55,058.08. Following the sale, the executive vice president directly owned 79,697 shares of the company’s stock, valued at $1,829,843.12. This trade represents a 2.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Kevin K. Gordon sold 2,500 shares of the firm’s stock in a transaction dated Monday, August 11th. The stock was sold at an average price of $22.04, for a total value of $55,100.00. Following the completion of the sale, the director directly owned 12,501 shares in the company, valued at $275,522.04. The trade was a 16.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 7,895 shares of company stock valued at $179,311 over the last ninety days. Corporate insiders own 9.40% of the company’s stock.

Hedge Funds Weigh In On Progyny

Several large investors have recently made changes to their positions in the business. Ameriprise Financial Inc. raised its holdings in Progyny by 37.6% during the 2nd quarter. Ameriprise Financial Inc. now owns 1,996,957 shares of the company’s stock valued at $43,933,000 after buying an additional 545,431 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main acquired a new stake in Progyny in the second quarter valued at approximately $4,670,000. Cubist Systematic Strategies LLC lifted its stake in shares of Progyny by 432.6% during the second quarter. Cubist Systematic Strategies LLC now owns 242,361 shares of the company’s stock worth $5,332,000 after buying an additional 196,856 shares during the period. Jump Financial LLC acquired a new stake in shares of Progyny during the second quarter worth $3,262,000. Finally, Qube Research & Technologies Ltd lifted its stake in shares of Progyny by 375.2% during the second quarter. Qube Research & Technologies Ltd now owns 174,693 shares of the company’s stock worth $3,843,000 after buying an additional 137,928 shares during the period. 94.93% of the stock is currently owned by hedge funds and other institutional investors.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.